Current research and management of ovarian cancer in China
Tóm tắt
Ovarian cancer is one of the most lethal malignant tumors in women in China, represents the third most common cancer after cervical cancer and endometrial cancer, and the first leading cause of death from gynaecological cancers. Due to the lack of effective screening strategies and the absence of symptoms in early-stage of disease, over 70% of patients present at an advanced stage. Despite the advances in surgical techniques and conventional chemotherapy, the prognosis of ovarian cancer has not been improved significantly, and indeed the long-term survival for patients with advanced disease does not exceed 20%. The aetiology of ovarian cancer remains poorly understood. In China, the major focus of research is to clarify the mechanism underlying ovarian cancer, develop more effective life-saving diagnostic and therapeutic measures, and undertake more population-based studies. This article summarizes current research, diagnosis and management of ovarian cancer in China.
Tài liệu tham khảo
Shen K. The progress and challenge of chemotherapy in ovarian cancer. Chin J Clin Obstet Gynecol, 2002, 3:3–7.
Shi YF, Ye DF, Lu WG,et al. Histological classification in 10 288 cases of ovarian malignant tumors in China. Chin J Obstet Gynecol, 2002, 37:97–100.
Lou P, Gu MJ. The epidemiology of ovarian cancer. In: Gu MJ (ed). Ovarian diease. Beijing: Science, 2001, 502–508.
Wang Y, Wang H, Peng Z,et al. Tissue array technique for p53 expression in human ovarian neoplasms. Chin J Obstet Gynecol, 2002, 37:405–407.
Liu L, Yang K. A study on C-erbB2, nm23 and p53 expressions in epithelial ovarian cancer and their clinical significance. Chin J Obstet Gynecol, 1999, 34:101–104.
Guan X, Lang J, Bian M. Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer. Chin J Obstet Gynecol, 1998, 33:165–167.
Sun Y, Shen Z, Ji X. Study on the relationship between CD44v6, p53 gene mutation and ovarian carcinoma metastasis. Chin J Obstet Gynecol, 2000, 35:225–228.
Zhang GL, Xu KL. Loss of heterozygosity at chromosome 3p in epithelial ovarian cancer in China. Int J Gynecol Cancer, 2002, 12:198.
Zhang H, Li Z, Chen M,et al. Loss of heterozygosity at chromosome 3p14, 25 in serum DNA from ovarian cancer patients. Chin J Obstet Gynecol, 2002, 37:298–300.
Sham JS, Tang TC, Fang Y,et al. Recurrent chromosome alterations in primary ovarian carcinoma in Chinese women. Cancer Genet Cytogenet, 2002, 133:39–44.
Khoo US, Chan KYK, Cheung ANY,et al. Recurrent BRCAI and BRCA2 germline mutations in ovarian cancer: a founder mutation of BRCA1 identified in the Chinese population. Hum Mutation, 2002, 486:1–7.
Tang NLS, Pang CP, Yeo W,et al. Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer. J Natl Cancer Inst, 1999, 91:882–885.
Shen K, Lang J, Huang R. Diagnosis and management strategies of hereditary ovarian cancer syndrome. Chin J Obstet Gynecol, 1996, 31:732–735.
Yang W, Zhang T, Fan J. The role of CA125 in the differential diagnosis of primary ovarian carcinoma and metastatic ovarian carcinoma originated from the gastrointestinal tract. Chin J Obstet Gynecol, 2001, 36:302–303.
Gu MJ. Ovarian diseases. Beijing: Science, 2001, 378–390.
Zang RY, Zhang ZY, Cai SM,et al. Cytoreductive surgery for stage IV epithelial ovarian cancer. J Exp Clin Cancer Res, 1999, 18:449–454.
Zang RY, Zhang ZY, Cai SM. Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma. Chin J Obstet Gynecol, 2002, 37:546–549.
Cui H. The surgical treatment of ovarian cancer. Chin J Clin Obstet Gynecol, 2001, 2:195–199.
Wang J, Zhang W. Restaging laparotomy of presumed early ovarian cancer. Chin J Obstet Gynecol, 2001, 36:672–674.
Shen K, Lang J, Lian L. Comprehensive staging laparotomy in stage I epithelial ovarian cancer. Chin J Obstet Gynecol, 1996, 31:390–394.
Wang CY, Gu MJ, Wang SX,et al. Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer. J Prac Obstet Gynecol, 2002, 18:228–229.
Huang H, Huang R, Pan L. High-dose chemotherapy with peripheralblood stem cells transplantation in patients with advanced gynecological malignant tumors. Chin J Obstet Gynecol, 2000, 35:486–489.
Yang XK, Chen JH, Xing H,et al. The relationship between caspase-3 activity and chemoresistance in cisplatin-resistance human ovarian cancer cell line COC1/DDP. Prog Obstet Gynecol, 2002, 11:321–324.
Huang J, Gu MJ, Chen C. Expression of glutathione S-transferase-pi in operative specimens as marker of chemoresistance in patients with ovarian cancer. Chin J Obstet Gynecol, 1997, 32:458–461.
Cheng G, Zhu H, Sun L,et al. The expression of multiple drug resistance associated genes in ovarian cancer. Chin J Obstet Gynecol, 2000, 35:87–90.
Shi W, Gu MJ, Liang LZ,et al. The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line. Chin J Obstet Gynecol, 1996, 31:79–82.
Gu MJ, Yang ZR, Qi XM,et al. The effect of chemotherapy after cytoreductive operation on the reproduction function and the offspring of patients with ovarian cancer. Chin J Obstet Gynecol, 1993, 28:343–345.
Tong XW, Shi W, Gu MJ,et al. Animal experiment on gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration in vivo. Chin J Obstet Gynecol, 1997, 32:712–714.
Zhang A, Lu Y, Wang S. Relationship between the expression of connexin 43 and bystander effect of suicide gene therapy in ovarian cancer. Chin J Obstet Gynecol, 2001, 36:542–545.
Yao Y, Peng Z, Wang H,et al. Anticancer effects of cytosine deaminase gene/5-fluorocytosine therapies to ovarian cancer in vivo. Chin J Obstet Gynecol, 2002, 37:195–197.
Li Y, Zhang Y, Li H,et al. Inhibition of recombinant rh gene adenovirus vector on the growth of ovarian cancer cell line. Chin J Obstet Gynecol, 2000, 35:98–100.
Huang X, Cai S, Fan J,et al. Combined treatment and prognostic analysis of advanced epithelial ovarian carcinoma. Chin J Obstet Gynecol, 2002, 37:291–293.
Lu Y, Zhang A, Wang S,et al. Role of vascular endothelial growth factor overexpression in ovarian tumor invasion and mechanism. Chin J Obstet Gynecol, 2002, 37:294–297.
Kong H, Jin Z, Yao M. Experimental therapy with angiogenesis inhibitor TNP-470 on human ovarian cancer transplanted subcutaneously in nude mice. Chin J Obstet Gynecol, 2002, 37:556–558.